raw materials – Page 22

Supplier change not evaluated during deviation investigation – inspection questions regulators ask

Evaluating Supplier Changes in Deviation Investigations: A Practical Playbook In the dynamic landscape of pharmaceutical manufacturing, changes in raw material suppliers can lead to significant quality challenges. When deviations occur,…

Inadequate vendor qualification during requalification – audit CAPA remediation framework

Addressing Inadequate Vendor Qualification During Requalification: A Comprehensive CAPA Remediation Framework In the pharmaceutical industry, the integrity of raw materials is paramount to ensuring product quality and safety. Inadequate vendor…

Supplier change not evaluated during deviation investigation – preventing batch rejection and recalls

Preventing Batch Rejection and Recalls from Supplier Change Evaluation Oversights In the competitive landscape of pharmaceutical manufacturing, oversight regarding raw materials can lead to significant operational challenges, such as product…

Vendor change implemented without approval during routine supplier audit – evidence pack for vendor oversight

Unauthorized Vendor Changes Detected During Routine Supplier Audits: An Investigative Approach In the dynamic landscape of pharmaceutical manufacturing, adherence to Good Manufacturing Practices (GMP) is paramount. A frequent challenge arises…

Raw material change implemented without assessment during regulatory inspection – preventing batch rejection and recalls

Proactive Strategies for Managing Raw Material Change During Regulatory Inspections The pharmaceutical manufacturing landscape is fraught with regulatory challenges, particularly around the management of raw materials. A raw material change…

Supplier audit findings escalated during regulatory inspection – audit CAPA remediation framework

Addressing Supplier Audit Findings Raised During Regulatory Inspections: A CAPA Framework In the pharmaceutical manufacturing environment, supplier audit findings can significantly impact compliance and product quality. Especially during regulatory inspections,…

Change control documentation gaps during deviation investigation – CAPA to prevent repeat failures

Addressing Documentation Gaps in Change Control During Deviation Investigations In the pharmaceutical manufacturing environment, the integrity of raw material change control is paramount. A failure in documentation can lead to…

Audit response ineffective during routine supplier audit – how to prevent repeat supplier failures

How to Address Ineffective Audit Responses During Routine Supplier Assessments In the highly regulated pharmaceutical landscape, maintaining the integrity of raw material supply chains is paramount. An ineffective audit response…

Specification change not communicated during deviation investigation – inspection questions regulators ask

How to Address Uncommunicated Specification Changes During Deviation Investigations In the highly regulated environment of pharmaceutical manufacturing, the failure to communicate changes in raw material specifications can severely impact product…

Supplier audit findings escalated during supply disruption – supplier risk classification strategy

Investigating Supplier Audit Findings During Material Supply Disruptions When a supplier audit uncovers significant findings amidst a material supply disruption, it can pose considerable risks to production quality and regulatory…

Unapproved material substitution during post-approval change review – inspection questions regulators ask

Managing Unapproved Material Substitution during Post-Approval Change Reviews In the pharmaceutical manufacturing landscape, the integrity of raw materials is paramount for compliance and product quality. Unapproved material substitutions can lead…

Audit response ineffective during regulatory inspection – how to prevent repeat supplier failures

How to Address Ineffective Audit Responses in Regulatory Inspections and Prevent Supplier Failures In the highly regulated pharmaceutical environment, ineffective audit responses during regulatory inspections can lead not only to…